Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
NCT04122716 on ClinicalTrials.gov · last registry update 2020-11-02
An unusually large phase 4: 215 participants, more than double the 75 typical for the stage. The sponsor logged completion for November 2019. Primary outcome, as filed: Body weight change (kg). liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Signe Torekov
- Sponsor type
- Other
- Enrollment
- 215
- Started
- 2016-09
- Primary completion
- 2019-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Body weight change (kg)
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.